Singapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management

Benzinga2021-11-24

iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc. Seelos will have exclusive worldwide rights for Wafermine, - for which...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

共同度过
2021-11-24
共同度过
起飞
- SmallYang:
  hopefully
Mumaizah
2021-11-24
Mumaizah
Ok
TradeMore
2021-11-24
TradeMore
Ok
- Catto:
  👍
kevinlaisq
2021-11-24
kevinlaisq
Lol
NPC69
2021-11-24
NPC69
K
bshian
2021-11-24
bshian
Ok
- edwinong:
  ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1115573252?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-24 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115573252","market":"us","top_or_hot":-1,"title":"Singapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management","media":"Benzinga","content":"<div>\n<p>iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc.\n\nSeelos will have exclusive worldwide rights for Wafermine, - for which...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270268/singapore-based-ix-biopharma-hands-seelos-exclusive-rights-for-wafermine-for-pain-management\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 20:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270268/singapore-based-ix-biopharma-hands-seelos-exclusive-rights-for-wafermine-for-pain-management><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc.\n\nSeelos will have exclusive worldwide rights for Wafermine, - for which...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270268/singapore-based-ix-biopharma-hands-seelos-exclusive-rights-for-wafermine-for-pain-management\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SEEL","symbol_name":"Seelos Therapeutics, Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24270268/singapore-based-ix-biopharma-hands-seelos-exclusive-rights-for-wafermine-for-pain-management","article_id":"1115573252","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115573252","pubTimestamp":1637756463,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine,","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SEEL":"Seelos Therapeutics, Inc."},"translate_title":"总部位于新加坡的iX Biopharma Hands Seelos对Wafermine用于疼痛管理的独家版权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SEEL":0.9},"content_text":"iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc.\n\nSeelos will have exclusive worldwide rights for Wafermine, - for which iX Biopharma will retain the rights.\nSeelos will also have worldwide rights to products incorporating R- and S- enantiomers of ketamine being developed using iX Biopharma's WaferiX technology.\nAs part of the deal, iX Biopharma will receive a $9 million upfront payment in cash and shares from Seelos. It is also eligible for up to $239 million in development and sales milestone payments.\nMoreover, iX Biopharma will receive \"double-digit\" percentage royalties on future net sales of any products which incorporate the R- and S- enantiomers of ketamine using its WaferiX technology.\n\"The licensing of the WaferiX drug delivery platform for sublingual (disintegrate under the tongue rapidly) ketamine broadens Seelos' ketamine franchise with formulations that we believe will be suitable for both acute and chronic dosing,\" said Raj Mehra, Chairman and CEO of Seelos.\nThe Licensed Products will contain ketamine, which provides a non-opioid approach for treating pain by targeting the NMDA receptor.\nPrice Action: SEEL shares closed at $1.95 on Tuesday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":874826126,"gmtCreate":1637760166215,"gmtModify":1637760166215,"author":{"id":"3500094346399605","authorId":"3500094346399605","name":"共同度过","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3500094346399605","idStr":"3500094346399605"},"htmlText":"起飞","listText":"起飞","text":"起飞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874826126","repostId":1115573252,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6707789,"gmtCreate":1637760281258,"gmtModify":1637760281360,"authorId":4088082610944870,"author":{"id":4088082610944870,"idStr":"4088082610944870","authorId":4088082610944870,"name":"SmallYang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874826126,"type":1,"supId":0,"prevId":0,"content":"hopefully","text":"hopefully","html":"hopefully"}],"langContent":"CN"},{"id":874823678,"gmtCreate":1637759955081,"gmtModify":1637759955081,"author":{"id":"4096632226898790","authorId":"4096632226898790","name":"Mumaizah","avatar":"https://static.tigerbbs.com/8fc41803d23fefb5d61d62d2d8bfa544","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4096632226898790","idStr":"4096632226898790"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874823678","repostId":1115573252,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874885081,"gmtCreate":1637757706647,"gmtModify":1637757706725,"author":{"id":"4097720712211120","authorId":"4097720712211120","name":"TradeMore","avatar":"https://static.tigerbbs.com/976c10f5e71e9a3b002205015f764d44","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4097720712211120","idStr":"4097720712211120"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874885081","repostId":1115573252,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6707349,"gmtCreate":1637757852041,"gmtModify":1637757852071,"authorId":3571577131047631,"author":{"id":3571577131047631,"idStr":"3571577131047631","authorId":3571577131047631,"name":"Catto","avatar":"https://static.tigerbbs.com/181aace79a405227ad1cfb4dcc27914c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874885081,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"CN"},{"id":874888388,"gmtCreate":1637757398003,"gmtModify":1637757398214,"author":{"id":"3572874548548490","authorId":"3572874548548490","name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3572874548548490","idStr":"3572874548548490"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874888388","repostId":1115573252,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874881486,"gmtCreate":1637757360874,"gmtModify":1637757361086,"author":{"id":"3584779133668268","authorId":"3584779133668268","name":"NPC69","avatar":"https://static.tigerbbs.com/47e7ac55312ae8dd1c9e7cb92adad089","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3584779133668268","idStr":"3584779133668268"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874881486","repostId":1115573252,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874880413,"gmtCreate":1637756877022,"gmtModify":1637756877143,"author":{"id":"3576896763784132","authorId":"3576896763784132","name":"bshian","avatar":"https://static.tigerbbs.com/ea8813b91ae8bba6f3905bb49e6986be","vip":1,"crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3576896763784132","idStr":"3576896763784132"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874880413","repostId":1115573252,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6707187,"gmtCreate":1637757052427,"gmtModify":1637757052455,"authorId":3581723087274150,"author":{"id":3581723087274150,"idStr":"3581723087274150","authorId":3581723087274150,"name":"edwinong","avatar":"https://static.tigerbbs.com/d42f3dae28f8c1740e66011b66f51ccd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874880413,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":64,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115573252"}